Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1242 participants.

Also called NCT02000115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,242 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02000115
Other papers using this trial's data
  • Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial Lancet (London, England), 2020-09-05 DOI, PubMed 32593323 PubMed links an erratum for this paper. Erratum: PMID 32619415

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02000115. Randomized; no masking; primary purpose treatment. Start 2014-05 (actual); primary completion 2019-10 (actual). Results posted on 2021-01-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Acronym
PORTICO-IDE
Condition
Aortic Valve Stenosis
Intervention (Device)
Portico transcatheter aortic valve
Intervention (Device)
Commercially available transcatheter aortic valve
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct02000115
Content hash
7ea19c9a08b22a9d9cefa244e424972dc20394036e5e55ede4d3b482d5c85a1b